BlackRock Amends BridgeBio Pharma Stake as of Dec 31, 2023
Ticker: BBIO · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1743881
| Field | Detail |
|---|---|
| Company | Bridgebio Pharma, Inc. (BBIO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock updated its BridgeBio Pharma stake, signaling a shift in its institutional holding.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, reporting its ownership in BridgeBio Pharma, Inc. as of December 31, 2023. This amendment, the third for BlackRock, indicates a change in their beneficial ownership of BridgeBio Pharma's Common Stock. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal their confidence (or lack thereof) in the company's future prospects, potentially influencing other investors.
Why It Matters
Large institutional investors like BlackRock often conduct extensive due diligence; their buying or selling activity can be seen as a vote of confidence or concern, influencing market sentiment and stock price.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not inherently signal high risk, but rather transparency.
Analyst Insight
Investors should monitor subsequent filings (like the full 13F for BlackRock) to understand the exact change in share count and percentage owned, which could provide more specific insights into BlackRock's updated position in BridgeBio Pharma, Inc.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- BridgeBio Pharma, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the date the SC 13G/A was filed
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and 'Amendment No: 3'.
Who is the 'subject company' in this filing?
The subject company is BridgeBio Pharma, Inc., as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.'.
Who is the 'filed by' entity in this document?
The entity that filed this document is BlackRock Inc., as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.'.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of BridgeBio Pharma, Inc. is 10806X102, as listed under 'CUSIP No. 10806X102'.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires the filing of this statement was December 31, 2023, as specified in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding BridgeBio Pharma, Inc. (BBIO).